Suppr超能文献

术后血清肌红蛋白作为肝移植后早期移植物功能障碍的预测指标。

Postoperative serum myoglobin as a predictor of early allograft dysfunction after liver transplantation.

作者信息

Zhang Jin, Han Yuzhen, Ke Shuhao, Gao Rongyue, Shi Xiaocui, Zhao Song, You Pan, Jia Huimiao, Ding Qi, Zheng Yue, Li Wenxiong, Huang Lifeng

机构信息

Department of Surgical Intensive Care Unit, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China.

Department of Intensive Care Unit, Chengde Medical University, China.

出版信息

Front Surg. 2022 Oct 12;9:1026586. doi: 10.3389/fsurg.2022.1026586. eCollection 2022.

Abstract

BACKGROUND

Early allograft dysfunction (EAD) is a common postliver transplant complication that has been associated with graft failure and risk for poor prognosis. There are many risk factors for the incidence of EAD after liver transplantation (LT). This study investigated whether elevated postoperative myoglobin (Mb) increases the incidence of EAD in liver transplanted recipients.

METHODS

A total of 150 adult recipients who measured Mb within 3 days after liver transplantation between June 2019 and June 2021 were evaluated. Then, all patients were divided into two groups: the EAD group and the non-EAD group. Univariate and multivariate logistic regression analyses were performed, and receiver operating characteristic curves (ROCs) were constructed.

RESULTS

The incidence of EAD was 53 out of 150 patients (35.3%) in our study. Based on the multivariate logistic analysis, the risk of EAD increased with elevated postoperative Mb (OR = 1.001, 95% CI 1.000-1.001, = 0.002). The Mb AUC was 0.657, and it was 0.695 when combined with PCT. When the subgroup analysis was conducted, the AUC of serum Mb prediction was better in patients whose preoperative model for end-stage liver disease score  ≤ 15 or operative time ≥ 10 h (AUC = 0.751, 0.758, respectively, or 0.760, 0.800 when combined with PCT).

CONCLUSION

Elevated Mb significantly increased the risk of postoperative EAD, suggesting that postoperative Mb may be a novel predictor of EAD after liver transplantation.The study was registered in the Chinese Clinical Trial Registry (Registration number: ChiCTR2100044257, URL: http://www.chictr.org.cn).

摘要

背景

早期移植物功能障碍(EAD)是肝移植后常见的并发症,与移植物衰竭及预后不良风险相关。肝移植(LT)后EAD发生有诸多危险因素。本研究调查术后肌红蛋白(Mb)升高是否会增加肝移植受者EAD的发生率。

方法

对2019年6月至2021年6月期间150例肝移植术后3天内检测Mb的成年受者进行评估。然后,将所有患者分为两组:EAD组和非EAD组。进行单因素和多因素逻辑回归分析,并构建受试者工作特征曲线(ROC)。

结果

本研究中150例患者中有53例发生EAD(35.3%)。基于多因素逻辑分析,EAD风险随术后Mb升高而增加(OR = 1.001,95%CI 1.000 - 1.001,P = 0.002)。Mb的AUC为0.657,与降钙素原(PCT)联合时为0.695。进行亚组分析时,术前终末期肝病模型评分≤15或手术时间≥10小时的患者血清Mb预测的AUC更好(分别为0.751、0.758,或与PCT联合时为0.760、0.800)。

结论

Mb升高显著增加术后EAD风险,提示术后Mb可能是肝移植后EAD的新型预测指标。该研究已在中国临床试验注册中心注册(注册号:ChiCTR2100044257,网址:http://www.chictr.org.cn)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87aa/9597078/091c4a58eabe/fsurg-09-1026586-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验